NBIXNeurocrine Biosciences Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 19023
Ticker: NBIX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1996-05-23
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: NBIX

Detail

Enriched 2026-08-14 20:47

Market cap: $15,907,080,334.69
Shares outstanding (class): 101,649,181
Shares outstanding (weighted): 101,649,181
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 2,500
Location: SAN DIEGO, CA
Homepage: https://www.neurocrine.com
Description: Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Market cap and share counts drift.

Funds holding this security

346 funds · 351 positions · $4.21B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
Dodge & Cox Stock Fund Dodge & Cox Funds	—	$522.22M	0.46%	3,964,000 NS	FIGI
iShares Core S&P Mid-Cap ETF iShares Trust	IJH	$437.22M	0.41%	3,318,802 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$421.08M	0.02%	3,196,296 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$304.86M	0.19%	2,314,127 NS	FIGI
JPMorgan Growth Advantage Fund J.P. Morgan Mutual Fund Investment Trust	—	$174.34M	0.86%	1,323,361 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$170.58M	0.44%	1,294,810 NS	FIGI
JPMorgan Mid Cap Growth Fund JPMorgan Trust II	—	$159.04M	1.39%	1,207,253 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$147.60M	0.18%	1,120,418 NS	FIGI
State Street SPDR S&P MidCap 400SM ETF Trust —	—	$99.65M	0.41%	756,448 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$95.84M	1.18%	727,502 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$86.16M	1.16%	654,044 NS	FIGI
iShares S&P Mid-Cap 400 Growth ETF iShares Trust	IJK	$80.42M	0.81%	610,411 NS	FIGI
VictoryShares Free Cash Flow ETF Victory Portfolios II	VFLO	$80.09M	1.30%	607,961 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$78.24M	3.45%	593,926 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$73.35M	0.39%	556,764 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERNBIX
FIGI_COMPOSITEBBG000GJS7C1
FIGI_SHARE_CLASSBBG001S8W4X9
CIK0000914475
ISINUS64125C1099
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine disorders, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.